Source: Eur Respir J, 56 (2) 2000268; 10.1183/13993003.00268-2020
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Brett Ley, Shuo Liu, Brett M. Elicker, Travis S. Henry, Eric Vittinghoff, Jeffrey A. Golden, Kirk D. Jones, Paul J. Wolters. Telomere length in patients with unclassifiable interstitial lung disease: a cohort study. Eur Respir J, 56 (2) 2000268; 10.1183/13993003.00268-2020

Member's Comments

No comment yet.

Related content which might interest you: Diaphragm ultrasound in patients with interstitial lung disease (ILD): a prospective study. Source: Virtual Congress 2021 – Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases Year: 2021 The association between leukocyte telomere length, telomere attrition and disease severity in cystic fibrosis patients Source: International Congress 2017 – Cystic fibrosis: monitoring and biomarkers Year: 2017 Telomere length and genetic variant associations with interstitial lung disease progression and survival Source: Eur Respir J, 53 (4) 1801641; 10.1183/13993003.01641-2018 Year: 2019 Outcomes of patients with progressive fibrosing interstitial lung disease (PF-ILD) – data from a prospective ILD registry Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis Year: 2021 Clinical characteristics of patients with unclassifiable interstitial lung disease Source: International Congress 2015 – New insights into IIPs Year: 2015 A single-centre retrospective study to phenotype unclassifiable interstitial lung disease Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 A review of patients following a diagnosis of unclassified interstitial lung disease (ILD) at a tertiary centre Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis Year: 2020 Diffuse interstitial lung disease (a retrospective analysis of 79 cases) Source: Eur Respir J 2002; 20: Suppl. 38, 61s Year: 2002 A cohort of patients with a progressive fibrosing phenotype of interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF): the PROGRESS study Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Measuring patient activation in an interstitial lung disease (ILD) population: an exploratory study Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 Early markers of cystic fibrosis structural lung disease: follow-up of the ACFBAL cohort Source: Eur Respir J, 55 (4) 1901694; 10.1183/13993003.01694-2019 Year: 2020 Gait speed and prognosis in patients with idiopathic pulmonary fibrosis: a prospective cohort study Source: Eur Respir J, 53 (2) 1801186; 10.1183/13993003.01186-2018 Year: 2019 Body composition and mortality in idiopathic pulmonary fibrosis (IPF): a prospective cohort study. Source: International Congress 2018 – Let’s interact and discuss the hot topics in pulmonary rehabilitation Year: 2018 A large cohort study of clinical outcomes and prognostic predictors in patients with acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2014 – IPF and surroundings Year: 2014 Frequency and characterization of sleep related disorders in interstitial lung disease patients: a prospective study Source: International Congress 2017 – Obstructive and central sleep apnoea: consequences and comorbidities Year: 2017 PROOF-registry: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting Source: International Congress 2014 – ILDs 6 Year: 2014 An observational study of incident diagnoses of children’s diffuse parenchymal lung disease (ChILDEU) Source: International Congress 2018 – Primary ciliary dyskinesia and lung function tests in respiratory morbidities Year: 2018 Final analysis of RECAP, an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment I Year: 2016 Unraveling unclassifiable interstitial lung disease – a multicenter approach Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis Year: 2020 Risk factors for lung disease progression in children with cystic fibrosis; a longitudinal cohort study Source: International Congress 2017 – Cystic fibrosis: treatments and monitoring Year: 2017